A randomized, controlled trial of oral midazolam and buffered lidocaine for suturing lacerations in children (the SLIC Trial).
OBJECTIVE
To evaluate the efficacy of oral midazolam (0.3 mg/kg) and buffered lidocaine in reducing the anxiety associated with the repair of childhood lacerations.


METHODS
Prospective, randomized, double-blind, placebo-controlled trial.


METHODS
Community-based emergency department.


METHODS
Children younger than 10 years.


METHODS
Each subject was randomized into one of four treatment groups: A, midazolam and buffered lidocaine (n = 25); B, placebo and buffered lidocaine (n = 27); C, midazolam and plain lidocaine (n = 32); and D, placebo and plain lidocaine (n = 23).


RESULTS
Anxiety level was scored on a scale of 1 to 4 on the basis of predetermined behavior criteria before and during repair. Parents independently rated the child's distress using a visual analog scale. Vital signs were measured on admission and at discharge. There were no significant differences among the treatment groups for age, location and length of laceration, or initial anxiety scores. Midazolam decreased the number of children with anxiety levels 3 and 4 by 24% (95% CI, 7.5% to 41.3%). There was a 33% reduction of the parents' distress rating with midazolam (P < .01). Buffered lidocaine had no effect on anxiety level.


CONCLUSIONS
Oral midazolam (0.3 mg/kg) is a safe and effective treatment for reducing anxiety during the suturing of lacerations in children less than 10 years of age. In this study, buffered lidocaine had no effect on anxiety level.
Department of Emergency Medicine, Swan District Hospital, Western Australia.
D M
DM
Fatovich
I G
IG
Jacobs
D000284:Administration, Oral; D000772:Anesthesia, Local; D001007:Anxiety / Q000209:etiology / Q000517:prevention & control*; D002021:Buffers; D002648:Child; D002675:Child, Preschool; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007223:Infant; D008012:Lidocaine / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008874:Midazolam / Q000627:therapeutic use*; D011446:Prospective Studies; D012867:Skin / Q000293:injuries*; D013537:Sutures; D014947:Wounds and Injuries / Q000628:therapy
D002021:Buffers; D008012:Lidocaine; D008874:Midazolam